Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Corticoids in ARDS Secondary to COVID-19
2020-001307-16Phase 3Terminated
- Sponsor
- Fundación para la Investigación Biomédica del Hospital Universitario Ramón y Cajal
- Start
- Apr 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in acute respiratory distress syndrome (ARDS) and Coronavirus disease 2019 pneumonia comparing Standard of care + methylprednisolone with Standard of care alone (2 arms). Primary endpoint: 28-day all-cause mortality. Started Apr 2020; status: terminated.
02
Drugs
methylprednisolone
03
Conditions
acute respiratory distress syndrome (ARDS)Coronavirus disease 2019 pneumonia
Beyond the preview
Go deeper on 2020-001307-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001307-16.